BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase)

In vivo, xenograft models further validated that BUB1 silencing significantly reduces tumor volume, accompanied by modulation of ferroptosis-related genes in tumor tissues. Collectively, our findings identify BUB1 as a novel prognostic biomarker and therapeutic target for LUAD, revealing a new regulatory mechanism by which BUB1 promotes LUAD progression through the activation of the STAT3/GPX4 axis to suppress ferroptosis.

Molecular docking identified three potential BUB1-targeting drugs (quercetin, cryptolepine, etoposide) with stable binding conformations. Collectively, our fingdings established BUB1 as a diagnostic biomarker for lung cancer, an independent prognostic indicator for LUAD, and a promising therapeutic target, with its inhibition potentially overcoming CSCs-driven treatment resistance.

This study identified six telomere-related genes with high expression and strong diagnostic value in ccRCC, highlighting their association with immune infiltration and potential as diagnostic and therapeutic targets.

This study revealed the important role of BUB1, one of the potential targets of 5-FU, in the development of esophageal cancer. Through bioinformatics analysis and experimental validation, we found that the high expression of BUB1 in esophageal cancer tissues was closely related to the biological properties of the tumor. the regulation of cell cycle by BUB1 and its role in the invasion and migration ability of the cells marked its potential as a new target for the treatment of esophageal cancer.

The identified miRNAs exhibit strong regulatory interactions with these hub genes, while serine/threonine protein kinases emerged as the most significantly associated group. Together, these findings highlight promising biomarker candidates and potential therapeutic targets for gynecological cancers.

BUB1 promotes the proliferation, migration, and invasion of esophageal cancer cells. Increased BUB1 expression is closely associated with tumor differentiation, lymph node metastasis, and clinical stage.

The results of the receiver operating characteristic (ROC) curve, area under the ROC curve, calibration plot, net reclassification index, integrated discrimination improvement index, and decision curve analysis revealed that the model had good discriminating ability, predictive ability, and clinical utility. In conclusion, AURKA, BUB1, and CDK1 are potential prognostic biomarkers of NPC, and a prediction model incorporating the expression levels of AURKA and BUB1 has good discriminating ability, predictive ability, and clinical utility.

Western blot and qRT-PCR tests validated these genes in GIST-T1 cells, and ssGSEA analysis indicated a significant relationship between these hub genes and immune cell infiltration. This study revealed a set of novel signature genes with high diagnostic value, offering promising targets for the diagnosis and treatment of GIST.

Moreover, BC cells with high MNAI increased sensitivity to microtubule-targeting agents such as docetaxel, paclitaxel, and ixabepilone but increased resistance to tamoxifen, AKT1/2 inhibitors, and mTOR inhibitors. Consistent with these findings, analysis of 16 clinical trial cohorts revealed that patients with high MNAI achieved higher pathological complete response rates to taxane-containing and ixabepilone-based therapies. Our findings demonstrate the MNAI as a clinically actionable biomarker that can refine risk stratification and guide the selection of targeted or chemotherapy regimens, advancing precision medicine in BC management.

This study identifies the BUB1/E2F1/TMPO-AS1/hsa-let-7b-5p axis as a potential prognostic biomarker and therapeutic target in LUAD. Targeting hsa-let-7b-5p may modulate this network, offering opportunities for both diagnostic and prognostic interventions.

9 core genes (CCNB1, CCNB2, MAD2L1, BUB1, TTK, CDC20, AURKA, RRM2, GTSE1) were obtained through the KEGG pathway enrichment, which mainly enriched in 4 pathways, namely, Cell cycle, Oocyte meiosis, p53 signaling pathway, and Progesterone-mediated oocyte maturation, respectively. Nine critical dependable DEGs were identified in limited-stage NSCLC using integrated bioinformatical approaches, and these core genes show great potential as prospective biomarkers and therapeutic targets in the progression of limited-stage NSCLC. non-small cell lung cancer, biomarkers, therapeutic targets, p53 signaling pathway, bioinformatics analysis.